Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (211-220 of 384) with videos related to

Pageof 39
Sort By:
Thrombosis Research|January 15, 1995
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparinD A Hoppensteadt, J M Walenga, A Fasanella, et al.
Thrombosis Research|January 1, 1993
Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogsL Iyer, J Shavit, M Koza, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin)W Jeske, B Lojewski, J M Walenga, et al.
Advances in Experimental Medicine and Biology|January 1, 1983
Inhibition of bradykinin-induced contraction of isolated smooth muscle tissue preparations by oligopeptide thiobenzyl ester substrates for serine proteasesJ Fareed, G Kindel, J M Walenga, et al.
Clinical Chemistry|September 1, 1983
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disordersJ Fareed, R L Bick, G Squillaci, et al.
Thrombosis Research|August 15, 1993
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal modelsP Bacher, J M Walenga, O Iqbal, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|August 26, 1998
[Acquired resistance to activated protein C in pregnancy]D M Schneider, G F von Tempelhoff, D Hoppenstaedt, et al.
Thrombosis Research|August 7, 1998
Ethylenediaminetetraacetic acid (EDTA) in heparinE Coyne, H L Messmore, J M Walenga, et al.
Thrombosis Research|May 15, 1988
Thrombin inhibition with dipeptidyl argininalsJ I Witting, C Pouliott, J L Catalfamo, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1986
Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transitionJ Fareed, J M Walenga, W H Baker, et al.
Pageof 39

Showing results (211-220 of 384) with videos related to

Sort By:
Pageof 39
Thrombosis Research|January 15, 1995
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparinD A Hoppensteadt, J M Walenga, A Fasanella, et al.
Thrombosis Research|January 1, 1993
Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogsL Iyer, J Shavit, M Koza, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin)W Jeske, B Lojewski, J M Walenga, et al.
Advances in Experimental Medicine and Biology|January 1, 1983
Inhibition of bradykinin-induced contraction of isolated smooth muscle tissue preparations by oligopeptide thiobenzyl ester substrates for serine proteasesJ Fareed, G Kindel, J M Walenga, et al.
Clinical Chemistry|September 1, 1983
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disordersJ Fareed, R L Bick, G Squillaci, et al.
Thrombosis Research|August 15, 1993
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal modelsP Bacher, J M Walenga, O Iqbal, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|August 26, 1998
[Acquired resistance to activated protein C in pregnancy]D M Schneider, G F von Tempelhoff, D Hoppenstaedt, et al.
Thrombosis Research|August 7, 1998
Ethylenediaminetetraacetic acid (EDTA) in heparinE Coyne, H L Messmore, J M Walenga, et al.
Thrombosis Research|May 15, 1988
Thrombin inhibition with dipeptidyl argininalsJ I Witting, C Pouliott, J L Catalfamo, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1986
Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transitionJ Fareed, J M Walenga, W H Baker, et al.
Pageof 39